Luigi Cavanna MD

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Chiara Citterio · 3 shared papers, 2018–2024 · strength 0.49
   • Paper FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison. DOI 10.21873/cdp.10303↗
   • Paper Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemother… DOI 10.18632/oncotarget.25639↗
   • Paper Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an atten… DOI 10.2147/ott.s200754↗
2. Elena Orlandi · 3 shared papers, 2018–2024 · strength 0.49
   • Paper FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison. DOI 10.21873/cdp.10303↗
   • Paper Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemother… DOI 10.18632/oncotarget.25639↗
   • Paper Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an atten… DOI 10.2147/ott.s200754↗
3. Stefano Vecchia · 2 shared papers, 2019–2024 · strength 0.38
   • Paper FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison. DOI 10.21873/cdp.10303↗
   • Paper Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an atten… DOI 10.2147/ott.s200754↗
4. Giovanni Gerardo Cardellino · 1 shared paper, 2025 · strength 0.19
   • Paper Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Applica… DOI 10.1016/j.esmoop.2024.104001↗
5. Marina Macchini · 1 shared paper, 2025 · strength 0.19
   • Paper Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Applica… DOI 10.1016/j.esmoop.2024.104001↗
6. Letizia Procaccio · 1 shared paper, 2025 · strength 0.19
   • Paper Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Applica… DOI 10.1016/j.esmoop.2024.104001↗
7. Elisa Giommoni · 1 shared paper, 2025 · strength 0.19
   • Paper Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Applica… DOI 10.1016/j.esmoop.2024.104001↗
8. Cidalia Maria de Sousa Pinto · 1 shared paper, 2025 · strength 0.19
   • Paper Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Applica… DOI 10.1016/j.esmoop.2024.104001↗
9. Silvia Bozzarelli · 1 shared paper, 2025 · strength 0.19
   • Paper Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Applica… DOI 10.1016/j.esmoop.2024.104001↗
10. Giulia Orsi · 1 shared paper, 2025 · strength 0.19
    • Paper Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Applica… DOI 10.1016/j.esmoop.2024.104001↗
11. Michèle Milella · 1 shared paper, 2025 · strength 0.19
    • Paper Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Applica… DOI 10.1016/j.esmoop.2024.104001↗
12. Michele Reni · 1 shared paper, 2025 · strength 0.19
    • Paper Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Applica… DOI 10.1016/j.esmoop.2024.104001↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.